Principles of chemistry /

nork Hiller, L. A., Herber, R. H.
Argitaratua 1960.

Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder

nork Hussain, S A, Ganesan, R, Hiller, L, Murray, P G, El-Magraby, M M, Young, L, James, N D
Argitaratua 2003

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial

nork Provenzano, E, Vallier, A-L, Champ, R, Walland, K, Bowden, S, Grier, A, Fenwick, N, Abraham, J, Iddawela, M, Caldas, C, Hiller, L, Dunn, J, Earl, H M
Argitaratua 2013

tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmona...

nork Wardley, A M, Hiller, L, Howard, H C, Dunn, J A, Bowman, A, Coleman, R E, Fernando, I N, Ritchie, D M, Earl, H M, Poole, C J
Argitaratua 2008

NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life

nork Earl, H M, Hiller, L, Dunn, J A, Bathers, S, Harvey, P, Stanley, A, Grieve, R J, Agrawal, R K, Fernando, I N, Brunt, A M, McAdam, K, O'Reilly, S, Rea, D W, Spooner, D, Poole, C J
Argitaratua 2008

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK

nork Earl, H.M., Hiller, L., Dunn, J., Macpherson, I., Rea, D., Hughes-Davies, L., McAdam, K., Hall, P., Mansi, J., Wheatley, D., Abraham, J.E., Caldas, C., Gasson, S., O'Riordan, E., Wilcox, M., Miles, D., Cameron, D.A., Wardley, A.
Argitaratua izan da Clin Oncol (R Coll Radiol) (2021)

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial

nork Ali, H. R., Dariush, A., Thomas, J., Provenzano, E., Dunn, J., Hiller, L., Vallier, A.-L., Abraham, J., Piper, T., Bartlett, J. M. S., Cameron, D. A., Hayward, L., Brenton, J. D., Pharoah, P. D. P., Irwin, M. J., Walton, N. A., Earl, H. M., Caldas, C.
Argitaratua izan da Ann Oncol (2017)

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negativ...

nork Earl, H. M., Hiller, L., Dunn, J. A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Gounaris, I., Abraham, J. E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J. M. S., Cameron, D. A., Provenzano, E., Thomas, J., Hayward, R. L.
Argitaratua izan da Ann Oncol (2017)

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised...

nork Earl, H M, Hiller, L, Dunn, J A, Vallier, A-L, Bowden, S J, Jordan, S D, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, D A, Agrawal, R, Fernando, I, Brunt, A M, O'Reilly, S M, Crawford, S M, Rea, D W, Simmonds, P, Mansi, J L, Stanley, A, McAdam, K, Foster, L, Leonard, R CF, Twelves, C J, Cameron, D, Bartlett, J MS, Pharoah, P, Provenzano, E, Caldas, C, Poole, C J
Argitaratua 2012